ArticleBioData mining2026
Iron homeostasis landscape informs patient survival and neoadjuvant chemotherapy response in cancer.
Article in BioData mining, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCancer cells frequently alter iron metabolism by increasing uptake or decreasing export, promoting oncogenesis and proliferation. However, the quantitative relationship between iron homeostasis and cancer remains underexplored. METHODS AND
resultsWe simplified these alterations into measurable changes in the expression levels of iron transport-related genes. We investigated the expression of iron transport-related genes by comparing genomic data of 478 human cancer cell lines to 105 normal tissue samples, as well as analyzing clinically paired 6903 tumor to 709 normal samples. We revealed that cancer cells exhibited increased expression of transferrin receptor 1 (TFR1) or CD44 for iron uptake and decreased expression of ferroportin for iron efflux to favor iron accumulation. Using machine learning, we identified TFR1, CD44, and ferroportin as the top three features consistently associated most with patient survival. We developed a cancer-specific iron risk score (CIRS) using parametric time-to-event models based on RNA-seq data from TFR1, CD44, and ferroportin in 4723 patients spanning 15 cancers. The CIRS, cross-validated in five external datasets, significantly stratified survival risk for various cancers, and predicted chemotherapy response in two independent breast cancer pharmacogenomic datasets.
conclusionsOur study enhances the understanding of the relationship between iron homeostasis, survival, and chemotherapy response, laying the groundwork for iron-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.